Homoharringtonine in combination with cytarabine and aclarubicin as induction therapy improves remission and survival of patients with higher risk myelodysplastic syndromes.
Xu
Wei-lai
WL
Institute of Hematology, First Affiliated Hospital of College of Medicine, Zhejiang University, Hangzhou, Zhejiang 310003, China.
Jin
Jie
J
Qian
Wen-bin
WB
D015250:Aclarubicin / Q000009:adverse effects / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D003561:Cytarabine / Q000009:adverse effects / Q000627:therapeutic use*; D004338:Drug Combinations; D005260:Female; D006248:Harringtonines / Q000009:adverse effects / Q000627:therapeutic use*; D000077863:Homoharringtonine; D006801:Humans; D008297:Male; D008875:Middle Aged; D009190:Myelodysplastic Syndromes / Q000188:drug therapy* / Q000401:mortality; D016896:Treatment Outcome; D055815:Young Adult
D004338:Drug Combinations; D006248:Harringtonines; D003561:Cytarabine; D000077863:Homoharringtonine; D015250:Aclarubicin